Valuation dashboard for Pyxis Oncology, Inc. (PYXS) with P/E N/A, P/B 19.38, EV/EBITDA -2.94 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
Analysis Summary
Trailing-twelve-month margins: gross margin 99.8%, operating margin -8.3%, net margin -8.0%.
At the current price of $3.34, PYXS has negative trailing earnings (P/E not meaningful) and an ROE of -215.23%. Market capitalisation stands at $212M.
Balance sheet quality for PYXS: current ratio of 3.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 19.38 |
| EV / EBITDA | -2.94 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.62 |
| vs Current Price | -51.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | $212M | 19.38 | -215.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.34 |
| Market Cap | $212M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -215.23% |
| Return on Invested Capital | -314.66% |
| Return on Assets | -161.55% |
| Gross Margin | 99.76% |
| Operating Margin | -834.44% |
| Net Margin | -803.83% |
Related companies: AVIR · CRBU · ENTA · FHTX · HUMA · IMRX · TNYA
Explore sector: Healthcare · Biotechnology
More sections of PYXS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks